Navigation Links
Soterix Medical Inc., Rogue Resolutions Ltd., and neuroConn GmbH announce MOBILE neuromodulation platform at NYCneuromodulation 2013 conference
Date:12/2/2013

NEW YORK, Dec. 2, 2013 /PRNewswire/ -- At the NYCneuromodulation 2013 conference, Soterix Medical Inc. , Rogue Resolutions Ltd, and neuroConn  GmbH announced the revolutionary MOBILE neuromodulation platform.  The product represents yet another collaboration between Soterix Medical Inc. (based in New York City, NY), Rogue Resolutions Ltd (based in Cardiff, UK), and neuroConn (based in Ilmenau, Germany).  Leveraging over five years of engineering innovations, the MOBILE neuromodulation system is the first non-invasive brain stimulation device designed for high-throughput clinical trials and potential home use.  The MOBILE stimulator is equipped with proprietary tDCS-Limited Total Energy (LTE) technology, which is the only technology optimized for low-energy neuromodulation.    

(Photo: http://photos.prnewswire.com/prnh/20131202/NY25821 )

Each patient receives a customized EASYstrap head-gear with an integrated MOBILE-stimulator. Compliance and safety is achieved through serial distribution of patient MOBILE-kits, each including: 1) A discharge-key that enables the MOBILE-stimulator and is programmed to provide 5 (five) timed sessions of therapy consistent with investigational treatment protocols, 2) Accessory packs including 5 (five) pairs of EASYfit or High-Definition electrodes ensuring consistent therapy thereby removing potential for patient error. Exclusive online MOBILE-smart analysis ensures proper set-up and use.  Discharge-keys are cloud enabled allowing remote physician supervision. 

When compliance and safety cannot be compromised, MOBILE Neuromodulation is the only system with fully integrated electrodes, head-gear, and MOBILE-smart electronics ensuring rigorous and consistent protocols. A system that is sufficiently advanced from any prior device; it could only be developed by the industry leaders in non-invasive neuromodulation. Ideal for extended trials and maintenance phases, the MOBILE device is expected to be deployed into major clinical trials throughout 2014. 

Dr. Abhishek Datta, CTO of Soterix Medical summarizes "In forming this partnership with Rogue Resolutions and neuroConn, an industry leader in neuromodulation engineering, Soterix Medical reaffirms its mission to provide clinical researchers and patients with the most advanced and tested brain stimulation technology.  The MOBILE system was designed to consider every eventuality in large-scale clinical trials and set-up. This is a complete system from patient set-up, to use, to cloud based compliance monitoring. The next generation EASYstrap customized to work with the MOBILE is the most robust and simple head-gear we have designed. Patients receive controlled supplies of electrodes and discharge-keys that are pre-programmed while the MOBILE stimulator includes the most intelligent monitoring systems available to ensure proper set-up. The stimulator itself has just one button.  Tremendous sophistication reduced to unmatched usability. "

BACKGROUND: tDCS- Limited Total Energy (tDCS-LTE) is an exclusive neuromodulation technology developed by Soterix Medical Inc. Invented at The City College of New York, tDCS-LTE is the only tDCS technology platform optimized for robust low-energy Transcranial Direct Current Stimulation. tDCS-LTE is under investigation in susceptible populations including stroke, pediatric, traumatic brain injury, etc. tDCS-LTE is made possible through a proprietary adaptive stimulation limiting the voltage and power required for tDCS. Soterix Medical tDCS-LTE is the only non-invasive neuromodulation technology further optimized for robust deployment in a wide variety of environments including emergency medicine, field-work, home-use, etc.

CAUTION: Investigational device. Federal (or United States) law limits device to investigational use.


'/>"/>
SOURCE Soterix Medical Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Soterix Medical Inc. reports positive results from High-Definition tDCS Fibromyalgia Trial at Harvard Medical School
2. Soterix Medical Inc. announces Phase 3 Clinical Trial for Depression comparing tDCS-LTE against antidepressant drug (Escitalopram)
3. Lung Cancer Alliance Congratulates 75 Medical Centers For Moving Swiftly And Responsibly On Lung Cancer Screening
4. Medical Device Developers - Network at BIOMEDevice Boston Next Week
5. Winner Medicals Special Committee Appoints Independent Financial Advisor and Retains Legal Counsel
6. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
7. CareFusion to Sell Neurodiagnostic Business to Natus Medical for $58 Million
8. ulrich medical USA™ Releases New Expandable Spinal Implant for US Market
9. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
10. Essential Medical Dismisses Patent Case against Masimo and Cercacor
11. Aethlon Medical Note: An Unprecedented Data Point, The Single-Treatment Capture of Hepatitis C Virus (HCV) by the Aethlon Hemopurifier®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)... March 1, 2017  Numotion, the nation,s leading provider ... of Tek RMD ("robotic mobilization device") by Matia Robotics ... RMD is a motorized standing movement device that offers ... wheelchair to complete everyday activities from a standing position. ... Tek RMD unassisted. Numotion is the exclusive distributor of ...
(Date:3/1/2017)... ... Research and Markets has announced the addition of the "Global ... The Global Infertility Therapy Partnering Terms and Agreements since ... entered into by the world,s leading healthcare companies. The ... are discovery or development stage whereby the licensee obtains a right ...
(Date:3/1/2017)... PRINCETON, N.J. , March 1, ... Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun ... today announced that several new analyses from Phase-1 ... and 2) of tildrakizumab, an investigational IL-23p19 inhibitor ... psoriasis, will be presented at the 2017 Annual ...
Breaking Medicine Technology:
(Date:3/1/2017)... ... ... After a long period of indulging in holidays, many individuals feel ready ... the detox categories, there is a rare yet successful way to cleanse the lungs ... Detox is an herbal-based formula designed to help cleanse people’s lungs from harmful chemicals ...
(Date:3/1/2017)... , ... March 01, 2017 , ... The Industrial Designers ... 5, 2017 by raising awareness of the profession of industrial design (ID) and relaunching ... content geared toward high school students and counselors; parents; and the greater public. , ...
(Date:3/1/2017)... ... March 01, 2017 , ... ... the release of its 2017 update to Compass, the popular online learning ... advisors. , Suitable for standardizing both new-hire on-boarding and annual competency-validation, Compass ...
(Date:3/1/2017)... ... 2017 , ... Grund® America is proud to announce the new ... March 2017 International Housewares Show in Chicago (Grund Booth N6466). , “We are very ... quality,100% OEKO-TEX and GOTS Organic Cotton material. By adding the GOTS (Global Organic ...
(Date:3/1/2017)... ... March 01, 2017 , ... Granite ... colorectal cancer screening rates by supporting the 80% by 2018 initiative, led by ... and the National Colorectal Cancer Roundtable (an organization co-founded by ACS and CDC). ...
Breaking Medicine News(10 mins):